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04 The Journal of Thoracic and Cardiobjectives: The outcomes of patients with metastatic melanoma are poor. Although
rognostic models have been developed to predict the occurrence of pulmonary
etastasis from cutaneous melanoma, few data exist to define the outcomes of these
atients once metastasis has occurred. The objective of this study was to discrim-
nate predictors of survival for patients with pulmonary metastatic melanoma.
ethods: We found 1720 patients with pulmonary metastasis listed in a prospective
omprehensive cancer center database of 14,057 consecutive patients with mela-
oma (Jan 1, 1970–June 1, 2004). Demographic and histopathologic data, time and
ocation of recurrences, number of pulmonary nodules, and subsequent therapies
ere collected. Univariate and multivariate Cox proportional hazards models were
sed to identify predictors of survival for patients with pulmonary metastatic
elanoma.
esults: The median survival was 7.3 months after development of pulmonary
etastasis. Significant predictors of survival from the multivariate model included
odular histologic type (P  .033), disease-free interval (P  .001), number of
ulmonary metastases (P  .012), presence of extrathoracic metastasis (P  .001),
nd performance of pulmonary metastasectomy (P  .001). Interactions were
dentified between metastasectomy and disease-free interval and presence of ex-
rathoracic metastasis. Surgery was associated with a survival advantage of 12
onths for patients with a disease-free interval longer than 5 years (19 vs 7 months,
 .01) and of 10 months for patients without extrathoracic metastasis (18 vs 8
onths, P  .01).
onclusions: When all other identified risk factors were controlled for mathemati-
ally, metastasectomy maintained a significant survival advantage for patients with
ulmonary metastatic melanoma. These data support the role of surgery for a select
ubset of patients with pulmonary metastasis.
n 2004, approximately 55,100 people in the United States were diagnosed with
cutaneous melanoma, and the incidence only continues to rise.1 Approximately
30% of patients with cutaneous melanoma have metastatic disease develop,
esulting in a dismal prognosis with a median survival of only 6 to 8 months and
-year survival of less than 5%.2,3 More than 80% of patients with metast
elanoma initially show only one distant organ site involved, most commonly the
ung.3-5 Approximately 40% of patients with metastatic melanoma initially s
solated pulmonary metastasis.3
Once distant metastasis has developed, the treatment options remain limited. This
s largely due to the failure of numerous systemic therapies, including chemother-
py, immunotherapy, and more recently molecular targeted agents, to improve
vascular Surgery ● January 2007
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TSverall survival in patients with stage IV disease. Surgical
herapy, however, has been shown in several studies to be
ssociated with a 5-year survival as high as 39%,6 as op-
osed to a 3% to 5% 5-year survival for nonsurgically
reated patients.2,7-10 These findings suggest that a sel
ubset of patients with pulmonary metastatic melanoma
ay benefit from metastasectomy. Several large studies of
atients with pulmonary metastatic disease have determined
rognostic factors for survival, but these have included
atients with a variety of primary tumor types and have
ailed to discriminate melanoma-specific prognostic factors.
he objective of this study was to discriminate predictors of
urvival in patients with pulmonary metastatic melanoma.
atients and Methods
atient Population
his study was reviewed and approved by the Duke institutional
eview board. Among the 14,057 patients with primary melanoma
ho were initially evaluated at the Duke Comprehensive Cancer
enter between January 1, 1970, and December 31, 2004, we
ound 1720 patients with metastatic pulmonary melanoma. The
atabase was prospectively maintained, and baseline demographic
ata, time and location of primary tumor, histopathologic data,
ubsequent therapies (immunotherapy, chemotherapy, nodal dis-
ections, and other resections), overall and cancer-specific surviv-
ls, and time and location of metastases were available for all
atients. All patients with primary melanoma were followed up by
linical examination every 6 months for 5 years after the initial
iagnosis and then annually thereafter. In addition, annual surveil-
ance chest radiography was routinely performed for all patients to
etect pulmonary metastasis.
tatistical Methods
nivariate and multivariate regression analyses with a Cox pro-
ortional hazards model were performed to examine the relation-
hip between potential prognostic factors and overall survival for
atients with metastatic pulmonary melanoma. The following vari-
bles were analyzed: age, sex, race, primary site, histologic type,
lark level, Breslow thickness, ulceration of the primary lesion,
egional lymph node status, number of pulmonary metastases,
isease-free interval between initial diagnosis and development of
ulmonary metastasis, presence of extrathoracic metastasis, sub-
equent therapies (immunotherapy and chemotherapy) and perfor-
ance of pulmonary metastasectomy. Predictor variables identi-
ed in the univariate analysis with a P value less than .1 were
urther examined in a multiple Cox proportional hazards model.
Overall survival was defined as the time between the initial
iagnosis of pulmonary metastasis and the date of last follow-up or
eath. Probabilities for development of pulmonary metastasis and
Abbreviations and Acronyms
CT  computed tomography
PET positron emission tomographyverall survival were estimated with the Kaplan–Meier method. m
The Journal of Thoracicaplan–Meier survival analyses stratifying on significant predictor
ariables identified in the multivariate analysis were also per-
ormed, and differences were tested with the log-rank test. Anal-
ses were carried out with Intercooled STATA version 9.0 soft-
are (Stata Corporation, College Station, Tex).
esults
he estimated risks of development of pulmonary metasta-
is for the entire melanoma population (n  13,565) were
3% at 5 years, 17% at 10 years, and 23% at 20 years after
nitial diagnosis (Figure E1). Patients who had unkno
rimary tumors or who had pulmonary metastasis at initial
resentation were excluded from this analysis (n  492).
he median follow-up of living patients was 65 months
0.1-524 months).
The overall survivals for patients with pulmonary meta-
tatic melanoma (n  1720) were 34% at 1 year, 14% at 2
ears, and 6% at 5 years (Figure E2). Patient demogr
nd melanoma histopathologic characteristics are displayed
n Table 1. The most common method of diagnosis
ulmonary metastatic melanoma was chest radiography (n
774). The remaining cases were diagnosed by chest
omputed tomography (CT, n  410), surgery (n  318),
ransthoracic needle aspiration (n  192), bronchoscopic
iopsy (n  18), and autopsy (n  8). For patients under-
oing surgery, the most common approach was unilateral
horacotomy (n  255), followed by thoracoscopic surgery
n  40) and bilateral thoracotomy (n  23). The most
ommon type of anatomic resection was stapled wedge (n
10), followed by lobectomy (n  96), segmentectomy (n
9), and pneumonectomy (n  3).
Among the demographic and histopathologic character-
stics, age older than 50 years (P  .01), African American
ace (P  .03), nodular histologic type (P  .01), Breslow
hickness (1-4 mm P  .01 and 4 mm P  .002), ulcer-
tion of the primary lesion (P  .003), positive regional
ymph nodes (P .001), more than 2 pulmonary metastases
P .001), disease-free interval (1 year P .001 and 1-5
ears P  .001), presence of extrathoracic metastasis (P 
001), and performance of pulmonary metastasectomy (P 
001) were found to be significant univariate predictors of
verall survival. When examined in a multivariate model,
odular histologic type, disease-free interval, number of
ulmonary metastases, presence of extrathoracic metastasis,
nd performance of pulmonary metastasectomy were found
o be independent predictors of overall survival (Table
Interactions were found between metastasectomy and
isease-free interval and presence of extrathoracic metasta-
is. Among patients with a disease-free interval longer than
years, surgery was associated with a survival advantage of
2 months (19 vs 7 months, P  .01). In patients without
vidence of extrathoracic metastasis, pulmonary metasta-
ectomy was associated with a survival advantage of 10
onths (18 vs 8 months, P  .01; Figure E4). After strat-
and Cardiovascular Surgery ● Volume 133, Number 1 105
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G
TSfication on number of preoperative risk factors identified in
he multivariate analysis, patients with no risk factors, 1 risk
actor, 2 risk factors, and 3 or more risk factors had 5-year
urvivals of 26%, 11%, 4%, and 2%, respectively (
re 1).
Two hundred forty-nine (78%) of the 318 patients who
nderwent metastasectomy had complete resection, and pa-
ABLE 1. Comparison of total patients, surgical patients, a
All patien
isk factor
ge (y)
No.  50 y 815
Mean SD 49
ale (No.) 1091
ace (No.)
White 1680
Black 38
Other 26
rimary site (No.)
Extremity 435
Trunk 678
Head and neck 386
Mucosal-genital/oral/rectal 54
Unknown 167
istologic type (No.)
Nodular 364
Acral lentiginous 98
Superficial spreading 678
Lentigo maligna 63
Other, not otherwise specified 517
lark level (No., n  1258)
I-II 77
III 386
IV-V 795
hickness (No. n  1085)
1 mm 140
1-4 mm 672
4 mm 273
lceration (No., n  1222) 434
ositive regional lymph node status (No., n  1600) 424
ulmonary metastases (No.)
1 473
2 186
3 75
4 986
nterval to pulmonary metastasis (No.)
1 y 395
1-5 y 911
5 y 414
t least 1 other distant, nonpulmonary metastasis 655
hemotherapy* 832
ontinuous and categorical variables were compared with the Student t-
dministered at any time after initial diagnosis of primary lesion.ients with incomplete resection were more likely to have s
06 The Journal of Thoracic and Cardiovascular Surgery ● Januultiple pulmonary metastases. Otherwise, there were no
ignificant differences with regard to histologic type, dis-
ases-free interval, or history of treated nonpulmonary dis-
ant metastasis (Table E1). Patients undergoing metastas
omy who had complete pathologic resection had a median
urvival of 19 months and a 5-year survival of 21%, com-
ared with a median survival of 11 months and a 5-year
onsurgical patients (n  1720)
1720) Surgical (n  318) Nonsurgical (n  1402) P value
) 150 (47%) 665 (47%) .93
47 15 49  15 .16
) 219 (69%) 872 (62%) .02
) 315 (94%) 1365 (97%) .01
) 3 (1%) 35 (2.5%) .1
) 18 (5%) 8 (0.5%) .001
) 73 (23%) 362 (26%) .29
) 122 (38%) 556 (40%) .67
) 83 (26%) 303 (22%) .08
) 5 (2%) 49 (3%) .08
) 35 (11%) 132 (9%) .39
) 59 (18%) 305 (22%) .21
) 7 (2%) 91 (6%) .003
) 121 (38%) 557 (40%) .58
) 21 (7%) 42 (3%) .002
) 110 (35%) 407 (29%) .051
) 23 (9%) 54 (5%) .02
) 76 (31%) 310 (31%)
) 148 (60%) 647 (64%)
) 43 (19%) 97 (11%) .006
) 134 (60%) 538 (63%)
) 48 (21%) 225 (26%)
) 50 (21%) 384 (39%) .001
) 63 (22%) 361 (27%) .088
) 240 (76%) 233 (17%) .001
) 49 (15%) 137 (10%)
) 13 (4%) 62 (4%)
) 16 (5%) 970 (69%)
) 53 (17%) 342 (25%) .001
) 165 (52%) 746 (53%)
) 100 (31%) 314 (22%)
) 61 (19%) 594 (42%) .001
) 99 (31%) 733 (52%) .001
2 test, and RC contingency tables when appropriate. *Chemotherapynd n
ts (n 
(47%
 15
(63%
(97%
(2%
(1%
(25%
(39%
(23%
(3%
(10%
(21%
(6%
(39%
(4%
(30%
(6%
(31%
(63%
(13%
(62%
(25%
(36%
(27%
(28%
(11%
(4%
(57%
(23%
(53%
(24%
(38%
(48%
test,urvival of only 13% for patients with incomplete resection
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G
TSP  .0001; Figure E5). Fifteen patients (5%) underw
epeated surgical resections. The median time to repeated
etastasectomy was 9  6.3 months. There was no signif-
cant difference in survival between patients undergoing
ingle metastasectomy and those patients undergoing re-
eated metastasectomies (median survivals 17 months and
5 months, respectively, P  .9).
iscussion
n this study, we found several independent prognostic
actors to be associated with overall survival for patients
ith pulmonary metastatic melanoma. Patients who had
odular histologic type of the primary lesion, greater num-
er of pulmonary metastases (2), shorter disease-free in-
erval (5 years), or evidence of extrathoracic metastasis
ad a poor prognosis, with a median survival of less than 8
onths. In contrast, patients selected for pulmonary metas-
asectomy were found to have a much higher median sur-
ival of 17 months. The greatest benefit from metastasec-
omy was realized in patients who had a prolonged disease-
ree interval of greater than 5 years and no evidence of
xtrathoracic metastasis.
igure 1. Overall survival by number of preoperative risk factors
n  1720).
ABLE 2. Independent predictors of overall survival in pat
redictor Hazard ra
odular histologic type 1.1
o. of pulmonary metastases 2 1.2
isease-free interval* 1.5
1 y
1-5 y 1.3
resence of extrathoracic metastasis 1.7
ulmonary metastasectomy 0.5
Reference category is disease-free interval longer than 5 years.g
The Journal of ThoracicDespite the many therapeutic advances that have been
ade during the past three decades for early-stage mela-
oma, the current treatment options for stage IV melanoma
emain limited. Chemotherapy with dacarbazine remains
he criterion standard, despite the lack of evidence of im-
roved survival for patients with stage IV disease.11 In
ddition, there remains no role for immunotherapy in pa-
ients with metastatic melanoma. The reported response
ates have been well below 20% for a variety of immuno-
herapies, including cytokines, monoclonal antibodies, and
accination strategies with synthetic peptides, naked DNA,
endritic cells, recombinant viruses, and so on.12 Unfortu-
ately, as a result of these dismal response rates and lack of
hase 3 studies demonstrating improved overall survival for
hese systemic agents, surgery remains the only hope for
mproved survival for a select subset of patients with stage
V disease.
Previous observational studies of patients with metastatic
elanoma have revealed varying results in identifying sig-
ificant prognostic factors; however, several variables have
emained constant from study to study, specifically the
umber of pulmonary nodules, the disease-free interval, and
he presence of extrathoracic metastasis.2,9,10,13 In our pre-
ious analysis, performed more than 15 years ago, regional
ymph node involvement and treatment with dacarbazine-
ased chemotherapy were found to be independent signifi-
ant predictors of survival; however, both of these had
uestionable clinical significance, with a survival advantage
f less than 2 months.9 In this larger analysis, these facto
ere not found to be significant predictors. The finding that
hemotherapy was not associated with survival is consistent
ith randomized controlled trials investigating the efficacy
f systemic therapy in this patient population.14-17
In contrast to systemic therapy, surgical management
ontinues to be the primary treatment modality for patients
ith metastatic melanoma. Unfortunately, surgery is not
ppropriate for all patients, and patient selection criteria
emain controversial. Although we did not directly deter-
ine predictors of survival among patients undergoing sur-
with pulmonary metastatic melanoma
95% Confidence interval P value
1.01-1.3 .033
1.04-1.4 .012
(1.3, 1.7) .001
(1.1, 1.4) .001
(1.6, 1.9) .001
(0.4, 0.6) .001ients
tioery, these patients typically had a limited number of lung
and Cardiovascular Surgery ● Volume 133, Number 1 107
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TSodules, no evidence of extrathoracic metastasis, and a
rolonged disease-free interval.
All surgical patients included in this analysis underwent
esection with curative intent only. None of the patients
ndergoing surgery in our series had grossly positive mar-
ins (R2). Incomplete resection in this study was defined as
ack of evidence of gross residual disease; on further histo-
ogic examination, however, the margins of the specimen
ere judged to be microscopically incomplete (R1). This
ay explain why patients with “incomplete resection” in
ur series had a 5-year survival of 13%, as compared with
0% 5-year survival in the study reported by Leo and
olleagues,10 in which incomplete resection was defined
ither R1 (microscopically incomplete) or R2 (grossly in-
omplete). There is evidence to suggest that by reducing the
umor burden, the immune system’s antitumor response
ay be enhanced.18 Together, these findings support t
ontinued use of metastasectomy for select patients with
elanoma and pulmonary metastasis.
The strengths of our study include prospective data col-
ection, complete follow-up on all patients, and large sample
ize. Despite our attempts to control for many of the poten-
ial selection factors by accounting for clinical and patho-
ogic characteristics of the metastasis, as well as character-
stics of the individual patients, our analysis is most likely
imited by patient selection bias. For example, it is chal-
enging to account for the judgment of individual surgeons
n determining eligibility for resection. In addition, we were
nable to account for other comorbidities that also may have
nfluenced the selection of patients for surgery and survival.
Although our study represents one of the largest series of
ulmonary metastasectomies for melanoma, another limita-
ion is that these data were collected during a span of 35
ears. As a consequence, changes in imaging technology
nd less-invasive surgical techniques may also have influ-
nced the selection and outcomes of patients. In an interna-
ional registry of lung metastasis of 2988 patients with
vailable preoperative radiologic and postoperative patho-
ogic assessments, accuracy rates of 61% and 75% were
eported for patients with bilateral and unilateral disease,
espectively. In addition, radiologic assessment was found
o underestimate number of pulmonary metastases by 16%
o 25%.13 Moreover, data from the recently completed N-
ional Lung Cancer Screening Trial (n  50,000) under-
core the accuracy of newer generation chest CT scans that
etect all lung abnormalities larger than 2 mm. Most pa-
ients in the earlier phase of our series had their disease
iagnosed by routine surveillance chest radiography alone;
owever, patients enrolled in the latter half of the study
nderwent CT, and more recently high-resolution helical
T with positron emission tomography (PET).
In addition, improvements in surgical technologies have
ed to an evolution of the standard approach for metasta-
08 The Journal of Thoracic and Cardiovascular Surgery ● Januectomy. Currently, we no longer routinely perform open
horacotomy at our institution, preferring limited-access
video-assisted) resections, either stapled wedge or lobec-
omy. This is accomplished by initially exploring the thorax
horacoscopically to inspect both the visceral and parietal
leural surfaces to exclude pleural dissemination. Pulmo-
ary nodules for intended resection are then located with
recise anatomic information from the CT scan and also by
alpation of lesions with a long, oval-ringed clamp (thora-
oscopic Foerster clamp). Occasionally, nodules in the an-
erior segments may also be palpated with the index finger
hrough the anterior access incision. It is possible that these
ifferences in operative technique may have also influenced
atient selection for metastasectomy.
Surgical therapy for pulmonary metastasis is not a new
reatment modality, as the first metastasectomy was per-
ormed more than 50 years ago,19 but controversy still exis
egarding the benefits of resection for patients with stage IV
elanoma. Several studies have demonstrated improved
urvivals of 18% to 39% for selected patients with pulmo-
ary metastasis undergoing resection, which is a significant
mprovement relative to the 5-year survival of 3% to 5% for
onsurgically treated patients.2,6-10 In our study of 172
atients, we also observed a significant survival benefit from
ulmonary metastasectomy for a subset of patients with
etastatic pulmonary melanoma. Our findings support the
ontinued use of surgical resection for patients with the
ollowing criteria: (1) limited number of pulmonary metas-
ases (2), (2) prolonged disease-free interval, and (3)
egative results of PET or CT scan for extrathoracic pul-
onary metastasis. A simple model that is based on number
f preoperative risk factors is provided as an aid for clini-
ians when selecting patients appropriate for metastasec-
omy (Figure E3).
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iscussion
r Joshua Robert Sonett (New York, NY). Dr Petersen, I con-
ratulate you and your colleagues on a nicely presented, well
ritten, and, I believe, important article. The Duke oncology
atabase has enabled the largest review of a single-center result of
ulmonary metastasectomy in melanoma. Importantly, the data-
ase includes both nonsurgical and surgical patients in the cohort.
he primary variable analysis was performed on 318 patients
ndergoing resection, a carefully selected cohort representing 18%
f all patients with pulmonary metastasis in your center. The
esults of the analysis are reassuring, nicely corroborating the
revious work presented by Ugo Pastorini of the international
egistry of lung metastases, a collaboration of US, Canadian, and
uropean centers. That collaborative registry was created to facil-
tate the study of results of pulmonary metastasectomy and to
ivine prognostic variables to guide treatment, much as your study
as. When the data were presented in 1997 with 5000 cases, 282
epresented patients with melanoma who underwent curative re-
ection. Overall survival of resected patients in that study was 21%
t 5 years. And although patients with melanoma histologic type
ad the worst prognosis of all those with solid tumors in that
eview, the nearly identical 5-year survival results presented today
learly confirm and validate the utility of pulmonary metastasec-
omy for select patients with metastatic melanoma. Additionally,
he international registry reported a follow-up study of 328 patients
n which four groups of risk-stratified variables were defined to
elp set the standards for delineating the role of metastasectomy in
elanoma. Again, these results and stratifications are nicely sim-
lar to your reported results, with the additional risk factors that
ou added of nodular histologic type and extrathoracic metastasis.
hat brings me to my first question.
Classically and sensibly, pulmonary metastasectomy with cur-
tive intent is reserved for patients without any evidence of ex- o
The Journal of Thoracicrathoracic disease. In your series, 20% of your patients undergo-
ng resection were defined as having other distant metastases.
lease explain why you brought these patients to resection and
ow you would deal with them in the future.
Two, given the similar results of the prognostic groups in the
nternational registry data, how do you think the addition of
odular histologic type helps us to decide which patients with
etastatic melanoma should undergo pulmonary resection or the
linical timing of the potential resection?
And finally, you noted that in the age of improved imaging your
roup preferentially now uses video-assisted thoracoscopic surgi-
al techniques for pulmonary metastasectomy. I wholeheartedly
upport this approach, but historically video-assisted thoracoscopic
urgical pulmonary metastasectomy has been considered contro-
ersial. Can you comment on this?
Again, I congratulate you on a well done and well presented
tudy, and thank the Association for the privilege of discussing this
resentation.
Dr Petersen. Thank you, Dr Sonett, for your insightful com-
ents and questions.
With regard to your first question about our 19% rate of
xtrathoracic metastasis, all such patients who underwent surgery
ither had a history of previous extrapulmonary resection or un-
erwent concurrent extrapulmonary resection. Although the rate
eems high at 19%, it is similar to the rate reported by Leo and
olleagues in the subset analysis of patients with melanoma only of
he international registry of lung metastases. The larger study by
astorino and colleagues, which included a variety of tumor types,
ctually showed a trend toward worse prognosis for patients with
revious or concurrent extrapulmonary resections, which is con-
istent with the findings in our study.
With regard to your question of how to use some of these
redictors that we have discriminated in our multivariate model,
uch as nodular histologic type or disease-free interval, one of the
gures that we presented revealed varying survival curves when
tratifying by number of preoperative risk factors. We believe it is
mportant to take into consideration all risk factors when deciding
hether the patient should undergo surgery. For instance if a
atient had nodular histologic type of the primary tumor but had a
rolonged disease-free interval, a limited number of pulmonary
etastases, and no evidence of extrathoracic disease, we would not
e dissuaded from surgery but would inform the patient of the
lightly higher mortality relative to patients without that risk
actor.
With regard to your last question about thoracoscopic surgery,
t is true that this subject remains controversial. We realize this is
ot standard of practice at many other institutions. Of the 318
atients with metastasis who underwent surgical resection in our
eries, 40 underwent resection by a thoracoscopic approach. All
hese patients were evaluated preoperatively by combined PET-CT
can, resulting in a low likelihood of having missed lesions larger
han 3 mm. The sensitivity of finding pulmonary metastasis from
elanoma by combined PET-CT scan has been previously re-
orted by Finkelstein and colleagues to be around 88%, with a
pecificity of 91%. The worst-case scenario for the small number
f patients with missed lesions not found by preoperative imaging
ould be to undergo a sequential thoracoscopic resection. More-
ver, there is no evidence to date that these missed lesions, found
and Cardiovascular Surgery ● Volume 133, Number 1 109
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G
TSntraoperatively by manual palpation through an open approach
nd probably measuring on the order of 3 mm or less, given the
ewest generation of high-resolution CT imaging and combination
ET-CT scan, are of any detriment to the patient.
Dr Mark J. Krasna (Baltimore, Md). Excellent presentation
nd good answers to those questions. Just one quick comment. In
oth colon cancer and renal cell carcinoma, we now have data on
he importance of lymph node metastasis. At many centers, we
ave actually begun to implement routine mediastinoscopy before
ttempting a curative metastasectomy. Although it only panned out
n your univariate analysis and did not show up in the Cox
egression analysis, would you comment on how you evaluate the
ediastinum in these patients with metastatic melanoma before
hey are taken to metastasectomy?
Dr Petersen. The regional lymph node status that showed up as
significant predictor in our univariate analysis had to do with the
rimary tumor only. The significance of positive mediastinal
ymph nodes to which you are alluding to remains unclear, how-
ver, especially in the setting of metastatic disease. Unfortunately,
his will never be answered unless lymph node dissection in
atients with pulmonary metastatic melanoma is uniformly prac-
iced. A maximum of only 9% of patients in the international
egistry of lung metastases underwent mediastinal lymph node
issection. Because currently most patients with suspected pulmo-
ary metastatic melanoma undergo wide margin wedge resection
nly without previous mediastinoscopy or concurrent lymph node
issection, this question will remain largely unanswered until we
ave a known denominator. e
10 The Journal of Thoracic and Cardiovascular Surgery ● JanuDr Frank C. Detterbeck (New Haven, Conn). I just want to
ollow up on Dr Sonett’s comment about video-assisted resection. We
nd others have shown that you still need to do palpation, even with
elical CT, because approximately 20% to 25% of patients will have
dditional metastases found on palpation despite helical CT. We have
one a follow-up study trying to look at factors that might have
redicted that. Was it that the radiologists were undercalling it? We
ave not been able to identify factors. So I think that if you are trying
o do a complete resection, you still need to palpate.
You must have decided that you weren’t going to try to do a
omplete resection; you were just going to see how many patients
ad follow-up nodules. Have you gone back and actually looked at
hat to provide some data on that?
Dr Petersen. No, we have not specifically looked at that
uestion in the metastasectomy series, but that is a very good point
nd something that we can look into in the future. The patients in
ur study that underwent thoracoscopic resection were evaluated
reoperatively with the latest generation of high-resolution CT and
ombined PET-CT. It is becoming standard practice at our insti-
ution to evaluate these patients with combined PET-CT, which as
e have previously discussed has high sensitivity and specificity,
aking it less likely to miss lesions larger than 3 mm. Unfortu-
ately, to date there are no data to support that going after all of the
ery small lesions that may or may not be found by aggressive
ntraoperative manual palpation through an open approach im-
roves overall prognosis. In fact, the likelihood of false positives
ncreases the smaller the lesion is, and by aggressively resecting all
hese, you may actually be jeopardizing pulmonary reserve; how-
ver, this remains largely unknown.
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TSigure E1. Risk of development of pulmonary metastasis (n 
3,565).
igure E2. Overall survival for patients with metastatic pulmo-
ary melanoma (n  1720).
igure E3. Overall survival by metastasectomy and disease-free
nterval (n  414).The Journal of Thoracic aigure E4. Overall survival by metastasectomy and presence of
xtrathoracic metastasis (n  1065).igure E5. Overall survival by complete resection, incomplete
esection, and nonsurgical treatment (n  1720).nd Cardiovascular Surgery ● Volume 133, Number 1 110.e1
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1
G
TSABLE E1. Surgery-only patients, by complete and incomp
isk factor Complete
istologic type (No.)
Nodular 47 (1
Acral lentiginous 7 (3
Superficial spreading 95 (3
Lentigo maligna 18 (7
Other, not otherwise specified 82 (3
ulmonary metastases (No.)
1 220 (8
2 24 (1
3 4 (1
4 1 (0
nterval to pulmonary metastasis (No.)
1 y 44 (1
1-5 y 123 (4
5 y 82 (3
xtrathoracic metastasis* 47 (1
ontinuous and categorical variables were compared with Student t-test,
f treated extrathoracic metastasis before undergoing pulmonary metastalete resection (n  318)
(n  249) Incomplete (n  69) P value
9%) 12 (20%) .78
%) 0 (0%) .16
8%) 26 (38%) .94
%) 3 (4%) .40
3%) 28 (40%) .24
.001
8%) 20 (29%)
0%) 25 (36%)
.5%) 9 (13%)
.5%) 15 (22%)
0.33
8%) 9 (13%)
9%) 41 (59%)
3%) 19 (28%)
9%) 14 (20%) 0.79
2 test, and RC contingency tables when appropriate. *Patients with history10.e2 The Journal of Thoracic and Cardiovascular Surgery ● January 2007
